OphRx

Our novel droplet technology provides enhanced bio-availability for both anterior and posterior segments of the eye. High solubility capacity transcends traditional limitations of size and polarity. the ability to achieve higher concentrations of known APIs enables treatment of severe cases, Improved safety and efficacy,reduced treatment burden, and targeted delivery capability enables topical treatment for posterior segment diseases like age related macular degeneration.